350997-39-6

Basic information

• Product Name: 3,4-DICHLORO-1-BENZOTHIOPHENE-2-CARBOHYDRAZIDE
• Synonyms: 3,4-DICHLORO-1-BENZOTHIOPHENE-2-CARBOHYDRAZIDE;OGG1 Inhibitor O8
• CAS NO: 350997-39-6
• Molecular Formula: C9H6Cl2N2OS
• Molecular Weight: 261.13
• Mol File: 350997-39-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3,4-DICHLORO-1-BENZOTHIOPHENE-2-CARBOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DICHLORO-1-BENZOTHIOPHENE-2-CARBOHYDRAZIDE(350997-39-6)
• EPA Substance Registry System: 3,4-DICHLORO-1-BENZOTHIOPHENE-2-CARBOHYDRAZIDE(350997-39-6)

Safety Data

• Hazardous Substances Data: 350997-39-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3,4-Dichloro-1-benzothiophene-2-carbohydrazide is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs with potential therapeutic applications.
Used in Anticancer Applications:
In the field of oncology, 3,4-Dichloro-1-benzothiophene-2-carbohydrazide serves as a potent and selective 8-oxoguanine DNA glycosylase 1 (OGG1) inhibitor, with an IC50 of 0.2 μM in a gel-based assay. Its high selectivity for OGG1 over other DNA glycosylases, such as NEIL1 and NTH1, makes it a promising candidate for the development of anticancer drugs. Inhibition of OGG1 can be utilized in monotherapy or in combination therapy to treat certain types of cancer.
Used in DNA Repair Research:
3,4-Dichloro-1-benzothiophene-2-carbohydrazide's ability to inhibit OGG1 also makes it a valuable tool in DNA repair research. Understanding the role of OGG1 in DNA repair mechanisms can provide insights into the development of novel cancer therapies and the potential use of 3,4-Dichloro-1-benzothiophene-2-carbohydrazide in targeted treatments.

Biochem/physiol Actions

OGG1 Inhibitor O8 is a potent inhibitor of 8-Oxoguanine DNA Glycosylase-1 (OGG1), part of the DNA base excision repair (BER) pathway that is becoming a drug target for cancer therapy. OGG1 Inhibitor O8 has an IC50 value of 220 nM and >100-fold selectivity for OGG1 relative to several other DNA repair glycosylases. O8 acts through the inhibition of Schiff base formation during OGG1 catalysis. It does not prevent DNA binding of OGG1 to a 7,8-dihydro-8-oxoguanine (8-oxo-Gua)-containing substrate.